Browsing Tag
Merck & Co.
35 posts
Bionyra raises $165m to build an immunology company from licensed assets
Bionyra launches with $165 million and three licensed immunology drugs. Read how its portfolio-first model could reshape biotech company creation.
Scancell confirms Neuphoria reverse-merger talks as SCLP targets Nasdaq and Phase 3 funding
Scancell is discussing an all-share acquisition of Neuphoria Therapeutics that could secure a Nasdaq listing and strengthen funding options for the global Phase 3 trial of iSCIB1+.
Merck (MRK) signs $510m AI drug discovery deal with Protillion Biosciences
Merck (MRK) signs a $510 million AI drug discovery deal with Protillion Biosciences, expanding its AI push ahead of the Keytruda patent cliff. Full analysis.
Has Akeso Inc. just exposed the next weak spot in standard lung cancer treatment?
Find out how Akeso Inc.’s ivonescimab survival data could reshape lung cancer treatment and challenge PD-1 drug combinations.
Can Kelun-Biotech and Merck turn sac-TMT into the first ADC plus immunotherapy standard in front-line lung cancer?
Merck needs life after Keytruda. Kelun-Biotech’s sac-TMT lung cancer data may show how the next oncology cycle takes shape.
Regeneron Pharmaceuticals’ LAG-3 gamble stumbles as Keytruda remains hard to beat in melanoma
Regeneron showed a PFS signal but missed the statistical bar. Keytruda remains the oncology benchmark investors still have to beat.
Merck’s $6.7bn Terns deal moves closer as TERN trades near offer price
Merck cleared a deal hurdle. TERN-701 now has to show whether one CML asset can justify a $6.7bn oncology bet.
Does CADENCE confirm a scalable pathway for treating complex pulmonary vascular disease beyond pulmonary arterial hypertension?
WINREVAIR’s Phase 2 data signals expansion beyond pulmonary arterial hypertension. Find out what this means for Merck & Co., Inc. and the market.
Is Merck & Co., Inc. embedding artificial intelligence at the core of its oncology strategy through Tempus AI integration?
Merck expands its Tempus AI collaboration to embed artificial intelligence into oncology research. What this means for MRK, TEM, and precision medicine.
Biggest pharma deals of 2025: How $70bn in M&A reshaped global drug strategy
Find out how Johnson & Johnson, Novartis, and Sanofi led the $70B pharma M&A wave in 2025, reshaping drug development strategy and investor confidence.